PrimeRFP SCOUT · Federal Contract Profile

Glaxosmithkline (FRHTPHMZMX47)Federal contracts · 11 recompetes

Glaxosmithkline holds $2.97B in federal volume across 194 award actions, with 100% at Department of Health and Human Services (HHS). SCOUT tracks 11 incumbent recompetes — an estimated $265.1M returning to market over the next 24 months (High exposure). Primary work: Pharmaceutical Preparation; Biological Product Manufacturing (95% prime). Obligations are down 16% year over year.

$2.97B

Federal Volume

Recompetes (24mo)

HHS

Top Agency · 100% firm-wide

194

Award Actions

Choose one — this changes what we ask next

Score my firm against Glaxosmithkline

Email me when a Glaxosmithkline recompete window opens.

Data through August 2026 · refreshed monthly · window Aug 2025 – Aug 2026

What they do

Capability

Service lines

PHARMACEUTICAL PREPARATION MANUFACTURING · BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Work mix: 95% prime · 5% sub · primary NAICS 325412 / PSC 6505 DRUGS AND BIOLOGICALS

Where they win

5 agencies

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%

Department of Defense (DOD)$1.7M · 0%

Department of Veterans Affairs (VA)$1.5M · 0%

Department of State (DOS)$1.2M · 0%

Department of Justice (DOJ)$772K · 0%

Recompete exposure: High · 11 in 24mo

Glaxosmithkline has an estimated $265.1M in contracts returning to market over the next 24 months.

Who buys from them

Agency buyer map

5 buyers

Department of Health and Human Services (HHS)217 awards · repeat buyer · $3.0B

Department of Defense (DOD)10 awards · repeat buyer · $1.7M

Department of Veterans Affairs (VA)108 awards · repeat buyer · $1.5M

Department of State (DOS)6 awards · repeat buyer · $1.2M

Department of Justice (DOJ)87 awards · repeat buyer · $772K

Recompete exposure & trajectory

Recompete exposure

High

Glaxosmithkline has an estimated $265.1M in contracts returning to market over the next 24 months. 4 within 6 months ($1.2M).

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E →

PIID: 75A50125F61019 · Expires 2026-08-30

$491K

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE S →

PIID: 75A50126F61020 · Expires 2026-10-29

$493K

GSK TRAVEL VACCINES →

PIID: 15F06724F0001366 · Expires 2026-12-31

$115K

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187 →

PIID: 15F06726F0000234 · Expires 2026-12-31

$105K

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND →

PIID: 75A50124F61014 · Expires 2027-02-21

$18.4M

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) TO SUPPORT THE COVID-19 FEDERAL RESPONSE- MULTI-DO →

PIID: 75A50124F61013 · Expires 2027-02-21

$15.4M

THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVANTS FROM PRIOR CONTRACTS FOR THE DEPARTMENT OF HEA →

PIID: 75A50124F61010 · Expires 2027-05-21

$40.9M

THE PURPOSE OF THIS HHS TASK ORDER IS TO PROCURE SERVICES FOR THE STORAGE AND STABILITY OF BULK LOTS & FINAL CONTAINERS OF-ADJUVANT( AS03) C →

PIID: 75A50124F61012 · Expires 2027-05-21

$14.0M

THE PURPOSE OF THIS TASK ORDER IS TO REQUEST THE FILL/FINISH OF ONE (1) CGMP ADJUVANT BULK LOT UNDER CLIN 0006E. FILL/FINISH AND RELEASE AS →

PIID: 75A50124F61009 · Expires 2027-05-21

$2.3M

THE PURPOSE OF THIS TASK ORDER IS TO PROCURE SERVICES FOR STORAGE AND STABILITY VACCINE BULK LOTS FROM PRIOR CONTRACTS FOR U.S. DEPARTMENT O →

PIID: 75A50124F61011 · Expires 2027-05-21

$1.1M

PURPOSE OF THIS MODIFICATION IS TO: 1. ACCEPT TRANSFER ACCOUNTABILITY OF 5,015,690 VIALS (50.1 MILLION DOSES) OF AS03 ADJUVANT FROM CONTRAC →

PIID: 75A50123F61005 · Expires 2027-12-31

$171.6M

Trajectory

▼ Consolidating-16% YoYFY2025 vs FY2024

'23

'24

'25

Teaming relationships

Glaxosmithkline teams with

ASD SPECIALTY HEALTHCARE, LLCas prime with

TEXAS A&M UNIVERSITY SYSTEM,THEas sub to

TRUSTEES OF BOSTON UNIVERSITY →as sub to

MESO SCALE DIAGNOSTICS, LLC →as sub to

UNIVERSITY OF SOUTHERN CALIFORNIA →as sub to

Partners from federal subaward / teaming records (public).

“SCOUT saves the hours of analysis that capture and proposal teams cannot afford to lose by delivering analyzed intelligence. Incumbent history, competitive positioning, and agency buying patterns get synthesized into…”

— Gwyne Taylor, Tailored Global

Explore another company

Don’t see your company?

Enter your company name and we'll build the page.

Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →

Frequently asked questions

What federal contracts does Glaxosmithkline hold?

Glaxosmithkline (UEI FRHTPHMZMX47) shows $3.0B across 194 award actions in SCOUT’s public USASpending-backed profile, with Department of Health and Human Services (HHS) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.

How much in federal contracts does Glaxosmithkline have?

Glaxosmithkline shows $3.0B across 194 award actions. SCOUT tracks 11 incumbent recompetes ($265.1M) returning to market in the next 24 months.

Which agencies does Glaxosmithkline work with?

Glaxosmithkline’s firm-wide obligated mix is led by Department of Health and Human Services (HHS) (100%), Department of Defense (DOD) (0%), Department of Veterans Affairs (VA) (0%).

What is the UEI for Glaxosmithkline?

The Unique Entity ID (UEI) for Glaxosmithkline is FRHTPHMZMX47.

Does Glaxosmithkline have contracts coming up for recompete?

Yes — SCOUT tracks 11 incumbent recompetes in the next 24 months (High exposure). Open the recompete section on this page for PIID-level timing.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.